OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
300412$5.3357

Zhejiang Canaan Technology Ltd

Industrial Machinery & EquipmentVerified

Zhejiang Canaan Technology Ltd maintains a market capitalization of 2.65 billion CNY and a price-to-earnings ratio of 89.5, indicating a high valuation relative to earnings. The company's liquidity position is characterized by a current ratio of 1.34, suggesting moderate short-term solvency, while its debt-to-equity ratio of 0.47 reflects a relatively conservative capital structure. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity of 2.82% and a return on assets of 1.17%, both below the typical thresholds for industrial machinery firms, indicating suboptimal capital efficiency. Gross profit of 293.88 million CNY and operating income of 32.16 million CNY suggest limited margin expansion, with operating margins at 2.61% and net margins at 2.41%. These figures fall below the median for the industry, highlighting a need for operational improvements. The company operates across four business segments: oral solid dosage equipment, biological and sterile preparation water systems, smart logistics, and pharmaceutical R&D services. Revenue concentration data is not explicitly provided, but the diversified nature of its offerings suggests a balanced geographic and product exposure. The robotics business, though not quantified in the financial snapshot, is a newer segment that may contribute to future growth. Outlook data indicates a modest revenue trajectory, with no significant growth expected in the current or next fiscal year. Capital expenditures of -39.38 million CNY suggest a reduction in investment, potentially signaling a strategic shift or financial constraint. The company's free cash flow of 9.43 million CNY is minimal, limiting its ability to reinvest or return capital to shareholders. Risk factors include a medium liquidity risk due to the current ratio and negative net cash position, as well as a low dilution risk based on the absence of near-term equity issuance plans. The company's debt structure is primarily long-term, with 489.11 million CNY in long-term debt, which may provide some stability but also increases interest burden. Recent events, including filings and transcripts, are not detailed in the provided data, but the company's financial performance and strategic direction suggest a focus on maintaining operations rather than aggressive expansion. The absence of recent capital raises or significant debt restructuring efforts implies a stable but cautious approach to financing.

30-day price · 300412-0.14 (-2.7%)
Low$4.91High$5.48Close$5.06As of15 May, 00:00 UTC
Profile
CompanyZhejiang Canaan Technology Ltd
Ticker300412.SZ
SectorIndustrials
BusinessIndustrial Goods
Industry groupIndustrial Goods
IndustryIndustrial Machinery & Equipment
AI analysis

Business. Zhejiang Canaan Technology Ltd designs, produces, and sells pharmaceutical equipment, including oral solid dosage equipment, biological and sterile preparation water systems, smart logistics solutions, and robotics, primarily serving the healthcare and industrial sectors.

Classification. The company is classified under the Industrial Machinery & Equipment industry within the Industrials economic sector, with a confidence level of 0.92.

Zhejiang Canaan Technology Ltd maintains a market capitalization of 2.65 billion CNY and a price-to-earnings ratio of 89.5, indicating a high valuation relative to earnings. The company's liquidity position is characterized by a current ratio of 1.34, suggesting moderate short-term solvency, while its debt-to-equity ratio of 0.47 reflects a relatively conservative capital structure. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity of 2.82% and a return on assets of 1.17%, both below the typical thresholds for industrial machinery firms, indicating suboptimal capital efficiency. Gross profit of 293.88 million CNY and operating income of 32.16 million CNY suggest limited margin expansion, with operating margins at 2.61% and net margins at 2.41%. These figures fall below the median for the industry, highlighting a need for operational improvements. The company operates across four business segments: oral solid dosage equipment, biological and sterile preparation water systems, smart logistics, and pharmaceutical R&D services. Revenue concentration data is not explicitly provided, but the diversified nature of its offerings suggests a balanced geographic and product exposure. The robotics business, though not quantified in the financial snapshot, is a newer segment that may contribute to future growth. Outlook data indicates a modest revenue trajectory, with no significant growth expected in the current or next fiscal year. Capital expenditures of -39.38 million CNY suggest a reduction in investment, potentially signaling a strategic shift or financial constraint. The company's free cash flow of 9.43 million CNY is minimal, limiting its ability to reinvest or return capital to shareholders. Risk factors include a medium liquidity risk due to the current ratio and negative net cash position, as well as a low dilution risk based on the absence of near-term equity issuance plans. The company's debt structure is primarily long-term, with 489.11 million CNY in long-term debt, which may provide some stability but also increases interest burden. Recent events, including filings and transcripts, are not detailed in the provided data, but the company's financial performance and strategic direction suggest a focus on maintaining operations rather than aggressive expansion. The absence of recent capital raises or significant debt restructuring efforts implies a stable but cautious approach to financing.
Key takeaways
  • Zhejiang Canaan Technology Ltd is a diversified industrial equipment manufacturer with a high valuation but weak profitability metrics.
  • The company's liquidity position is moderate, with a current ratio of 1.34 and a debt-to-equity ratio of 0.47.
  • Return on equity and return on assets are below industry norms, indicating inefficiencies in capital use.
  • Revenue growth is expected to remain flat, with limited reinvestment capacity due to low free cash flow.
  • The company's risk profile is characterized by medium liquidity risk and low dilution risk.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$1.23B
Gross profit$293.9M
Operating income$32.2M
Net income$29.6M
R&D
SG&A
D&A
SBC
Operating cash flow$184.5M
CapEx-$39.4M
Free cash flow$9.4M
Total assets$2.53B
Total liabilities$1.48B
Total equity$1.05B
Cash & equivalents
Long-term debt$489.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$5.33
Market cap$2.65B
Enterprise value$3.14B
P/E89.5
Reported non-GAAP P/E
EV/Revenue2.5
EV/Op income97.7
EV/OCF17.0
P/B2.5
P/Tangible book2.5
Tangible book$1.05B
Net cash-$489.1M
Current ratio1.3
Debt/Equity0.5
ROA1.2%
ROE2.8%
Cash conversion6.2%
CapEx/Revenue-3.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Industrial Goods · cohort 13 companies
Metric300412Activity
Op margin2.6%9.4% medp25 9.4% · p75 9.4%bottom quartile
Net margin2.4%5.8% medp25 5.8% · p75 5.8%bottom quartile
Gross margin23.9%26.9% medp25 26.9% · p75 26.9%bottom quartile
R&D / revenue2.0% medp25 1.6% · p75 3.0%
CapEx / revenue-3.2%2.4% medp25 1.6% · p75 3.3%bottom quartile
Debt / equity47.0%106.4% medp25 106.4% · p75 106.4%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 17:17 UTC#93ca2839
Market quoteclose CNY 5.33 · shares 0.50B diluted
no public URL
2026-05-04 10:47 UTC#83c581cd
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 10:49 UTCJob: 5d443b86